In the last trading session, 2.7 million shares of the Twist Bioscience Corp (NASDAQ:TWST) were traded, and its beta was 2.42. Most recently the company’s share price was $39.68, and it changed around $2.57 or 6.93% from the last close, which brings the market valuation of the company to $2.37B. TWST currently trades at a discount to its 52-week high of $60.90, offering almost -53.48% off that amount. The share price’s 52-week low was $27.41, which indicates that the current value has risen by an impressive 30.92% since then.
Twist Bioscience Corp stock received a consensus recommendation rating of Buy, based on a mean score of 1.77. If we narrow it down even further, the data shows that 0 out of 12 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended TWST as a Hold, whereas 6 deemed it a Buy, and 1 rated it as Underweight. Twist Bioscience Corp is expected to report earnings per share of -0.57 for the current quarter.
Twist Bioscience Corp (NASDAQ:TWST) trade information
Instantly TWST has showed a green trend with a performance of 6.93% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 42.64 on recent trading dayincreased the stock’s daily price by 6.94%. The company’s shares are currently down -14.61% year-to-date, but still down -2.77% over the last five days. On the other hand, Twist Bioscience Corp (NASDAQ:TWST) is -24.23% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $56, which translates to bulls needing to increase their stock price by 29.14% from its current value. Analyst projections state that TWST is forecast to be at a low of $54 and a high of $58.
Twist Bioscience Corp (TWST) estimates and forecasts
The year-over-year growth rate is expected to be 20.16%, up from the previous year.
Consensus estimates provided by 10 financial analysts predict the company will bring in an average of 92M in revenue for the current quarter. 10 analysts expect Twist Bioscience Corp to make 95.71M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 75.3M and 81.46M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 22.18%. Forecasts for the next quarter put sales growth at 17.48%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 1.70%. Twist Bioscience Corp earnings are expected to increase by 43.45% in 2025, but the outlook is positive 37.54% per year for the next five years.
TWST Dividends
Twist Bioscience Corp’s next quarterly earnings report is expected to be released in April.
ARTISAN PARTNERS LIMITED PARTNERSHIP, with 10.4371% or 6.07 million shares worth $299.06 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 3.06 shares worth $121.58 million, making up 5.14% of all outstanding shares. On the other hand, ARK ETF Tr-ARK Genomic Revolution ETF held roughly 2.16 shares worth around $85.67 million, which represents about 3.62% of the total shares outstanding.
